Symposium Agenda
| TIME | SESSION | DESCRIPTION | SPEAKERS | ||
|---|---|---|---|---|---|
| 8:00 AM – 9:00 AM | Networking & Registration | ||||
| 8:00 AM – 9:00 AM | Breakfast | ||||
| 9:00 AM – 9:15 AM | Opening Remarks | Rachel Robinson Chief Operating Officer MassMEDIC | |||
| 9:15 AM – 10:00 AM | Targeting 2030: Market Dynamics | The healthcare delivery landscape is evolving rapidly, compelled by simultaneous forces on multiple fronts. Provider networks are consolidating and facing economic pressures from strained legacy operating models and a rising tide of more financially motivated ownership. Demand continues to escalate as the population grows more numerous, older, and less active. Pervasiveness of technology and data are reshaping the expectations of patients, providers, and payors. Join us as we discuss how these dynamics converge, their potential implications for device manufacturers, and what opportunities and challenges we can expect in 2030. | Chris Coburn Chief Innovation Officer Mass General Brigham Antonio Sanchez Cordero Principal Archimed Maureen Halligan VP, Advisory & Innovation Services Cambridge Consultants Jeff Valk CEO Admetsys | ||
| 10:00 AM – 10:15 AM | Networking Break | ||||
| 10:15 AM – 11:00 AM | Engaging in 2030: Centers of Gravity | The “med” and “tech” nucleus of our industry is advertised up front. But clinical and engineering chops alone are profoundly insufficient to guarantee product success. New stakeholders have entered the arena and gained clout. Balances of power have shifted. Who will drive purchasing decisions in 2030 and what motivates and constrains them? How do we design and build products that are in step with modern consumer preferences and social priorities, as expressed both through the market and via regulations? Our panelists examine the changing face of market demand and the nature of products best positioned to meet it. | Lisa Brady Vice President, Global Sustainability | Chief Sustainability Officer Insulet Corporation Bryan Lord CEO Pristine Surgical Bill Peine, PhD VP of Surgical Research & Technology Medtronic Todd Usen CEO Adagio Medical | ||
| 11:00 AM – 11:15 AM | Networking Break | ||||
| 11:15 AM – 12:00 PM | Planning for 2030: Lessons from the Last Five Years | The last five years have been tumultuous and unrelenting in the medtech industry. They’ve also been profoundly instructive in the need for contingency strategy, and its evolution and use to ensure business continuity. Setting our organizations up for predictable operation and protecting our customers from supply interruptions are core to what we do. New challenges are coming. With borders less open today than they have been, how do we weigh and mitigate geopolitical risk while benefiting from the global supply chain? How do we address the need for continual supply of skilled work when the labor market becomes volatile or irregular? How do we fortify digital and physical operations together? We invite you to expect the unexpected with us, as our expert panel looks at organizational resilience and adaptability. | Irene Barquero Senior Director of Operations Hologic Marie O’Malley Senior Vice President of Commercial Operations PiSA USA Shalene Thomas Senior Emerging Contaminants Program Manager Battelle Elijah White President Zoll Acute Care Technology | ||
| 12:00 PM – 1:00 PM | Lunch Buffet & Networking | ||||
| 1:00 PM – 1:15 PM | Transition Time | ||||
| 1:15 PM – 2:00 PM | Breakout Session 1 with Three Concurrent Tracks | ||||
| 1A: Cardiac Health | Talking Tech A conversation with experts sharing insights from the frontiers of the cardiovascular market. This panel of cardiac innovators will discuss what trends we are seeing in product and clinical successes driving medtech forward. | Lori Chmura CEO Nyra Medical Shuja Dawood Director, New Business Development Boston Scientific Holly Scott Senior Partner The Mullings Group Peter Van Haur CEO Vital Connect | |||
| 1B: Musculoskeletal Health | Talking Tech A conversation with experts sharing insights from the frontiers of the musculoskeletal market. This panel of MSK innovators will discuss what trends we are seeing in product and clinical successes driving medtech forward. | Brian Quist Senior R&D Director Smith + Nephew Juliane Ray General Manager, Medtech Clarivate Todd Saunders Vice President, Marketing Osteal Therapeutics Howard Tang Global Strategic Marketing, Sports Johnson & Johnson MedTech | Orthopaedics | |||
| 1C: Diabetes | Talking Tech A conversation with experts sharing insights from the frontiers of the diabetes market. This panel of diabetes innovators will discuss what trends we are seeing in product and clinical successes driving medtech forward. | Ed Damiano Founder Beta Bionics Caroline Irungu Senior Sales Director Dassault Systemes Colleen Riley, OD, MS Chief Technology Officer Medtech Executive | |||
| 2:00 PM – 2:15 PM | Networking Break | ||||
| 2:15 PM – 3:00 PM | Breakout Session 2 with Three Concurrent Tracks | ||||
| 2A: Cardiac Health | Focus: The Narrow and the Broad When entering a new product market, time and financial resources are at a premium. It’s imperative that a company be laser-focused in getting first product into the market to validate, de-risk, gain experience, and build credibility — even if the launch product and its indications only address a small portion of the true technical and clinical potential. How does a successful company establish near-term focus while seeing and setting up for the bigger picture? What are the team culture and management dynamics that underlie this? This conversation will feature the perspective of both early stage and commercially successful companies as they discuss an indispensable pattern in cardiac care and medical devices more broadly. | Sonya Bhavsar Senior Director, Product Development Johnson & Johnson MedTech | Heart Recovery Michael Ferguson, PhD Vice President of Healthcare Economics and Reimbursement AtriCure Kate Rumrill Health Care Executive Jeff Valk CEO Admetsys | |||
| 2B: Musculoskeletal Health | The Great Migration Few specialties have as many elective procedures as MSK; and more important than ever is the environment in which these elective procedures are being performed. As we contemplate a future in which patients might select a hip replacement by make, model, and price as they would a consumer appliance or car, the design and orientation of products necessarily morphs. How does a shift from surgeon focus to patient focus impact our product thinking? What role does pricing play? In what markets should we expect more realization, and how does this shape our approaches? | Morgan Francis Commercial Marketing Director, Arthroscopic Enabling Technologies Smith+Nephew Scott Fraser Founder & Managing Partner Fraser Healthcare Raj Stewart Practice Lead, US MedTech Market Access Consulting IQVIA Medtech | |||
| 2C: Diabetes | Technology in Access to Individualized Care Diabetes care is a life-long, multi-faceted proposition in which one size does not fit all. For people living with diabetes, access to resources best suited to their care needs can be the difference between positive health outcomes and negative ones, with the latter imposing substantial financial costs on payors and society at large. Two key dimensions to bridging this divide are space and time: well suited care resources exist; but are they available where individuals can access them when they need them? Technology can address this; and our journey is only beginning. Join our panel as we discuss the future of technology in enhancing access to maximally effective, individually tailored care. | Jeff Abraham Partner Health Advances Diana Gelston Chief Commercial Officer Best Buy Health Paula LeClair Senior VP HomeCare Butterfly Network David Linders Co-Founder and Chief Product Officer Podimetrics | |||
| 3:00 PM – 3:15 PM | Networking Break | ||||
| 3:15 PM – 4:00 PM | Breakout Session 3 with Three Concurrent Tracks | ||||
| 3A: Cardiac Health | Tales from the Other side: A Fireside Chat The big pivot meets with big success: it’s the stuff of legend…and when the curtain is peeled back, lessons hard learned. Sometimes overnight success takes a while. Join us for an in-depth conversation with Mike Minogue, former CEO of Abiomed, as we dig into lessons learned from a journey in medtech. | Michael Minogue President & CEO Minogue Consulting Joe Mullings Founder, Chairman & CEO The Mullings Group Companies | |||
| 3B: Musculoskeletal Health | Taking on Policy “What Ifs?” Regardless of politics, there is policy. And when policy changes, the opportunity landscape changes. Business approaches and product positioning that were recently strong may encounter new obstacles; and ones that were previously nonviable may become open doors. In order to be successful, companies must evaluate strategy in context. Our industry experts will lay out various scenarios, rooted in potential policy updates, and discuss how companies may capitalize on each. | Anthony DeMaio Senior Vice President ML Strategies Mira Leiwant VP, Regulatory, Quality, Clinical Affairs Anika Therapeutics, Inc. Paul Seltman Senior Vice President, Global Public Policy & Government Affairs Smith+Nephew Mike Sroczynski Executive Vice President & General Counsel Massachusetts Health & Hospital Association | |||
| 3C: Diabetes | Drug Delivery: A Gold Standard? When it comes to drug delivery, it would appear that the diabetes sector of the medtech industry has it “figured out.” Wearable, minimal, ergonomic devices featuring a strong user-focus have achieved tremendous commercial success for both continuous administration of medication and diagnostic monitoring of diabetes. Relative outsiders in the drug creation space have noticed. What are the characteristics upon which this success is predicated? Are these attributes portable or replicable to medical uses outside of diabetes? This panel will examine the factors for the sector’s success, lessons learned, and how we might apply these in other clinical areas. | Mitali Aon SVP & Global Head Devices & Packaging Sanofi Ravi Kaushik VP, Head of Global Device, Digital Development & Product Strategy Plasma Derived Therapies (PDT) R&D Takeda Jason O’Connor Vice President of Next Generation Platforms Insulet Corporation Amy Siegel CEO S2N Health | |||
| 4:00 PM | Symposium Concludes |
GALA Agenda
| TIME | SESSION | ||
|---|---|---|---|
| 6:00 PM | Registration for the Gala Opens, Cocktail Reception | ||
| 7:00 PM | Dinner & Program | ||
| 9:00 PM | Dessert Reception | ||
| 10:30 PM | Gala Concludes |